Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 1.48 SEK 0.54%
Market Cap: 312.7m SEK

Intrinsic Value

ONCO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ONCO stock under the Base Case scenario is 2.44 SEK. Compared to the current market price of 1.48 SEK, Oncopeptides AB is Undervalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ONCO Intrinsic Value
2.44 SEK
Undervaluation 39%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Oncopeptides AB

Valuation History Unavailable

Historical valuation for ONCO cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare ONCO to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ONCO?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Oncopeptides AB
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oncopeptides AB

Current Assets 148.6m
Cash & Short-Term Investments 107.2m
Receivables 35.4m
Other Current Assets 6m
Non-Current Assets 24.8m
Other Non-Current Assets 24.8m
Efficiency

Free Cash Flow Analysis
Oncopeptides AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Oncopeptides AB

Revenue
39.8m SEK
Cost of Revenue
-2.3m SEK
Gross Profit
37.6m SEK
Operating Expenses
-315.2m SEK
Operating Income
-277.7m SEK
Other Expenses
99k SEK
Net Income
-277.6m SEK
Fundamental Scores

ONCO Profitability Score
Profitability Due Diligence

Oncopeptides AB's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
ROIC is Increasing
Positive 3Y Average ROE
Exceptional Gross Margin
46/100
Profitability
Score

Oncopeptides AB's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

ONCO Solvency Score
Solvency Due Diligence

Oncopeptides AB's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
41/100
Solvency
Score

Oncopeptides AB's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ONCO Price Targets Summary
Oncopeptides AB

Wall Street analysts forecast ONCO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONCO is 5.79 SEK with a low forecast of 1.72 SEK and a high forecast of 14.7 SEK.

Lowest
Price Target
1.72 SEK
16% Upside
Average
Price Target
5.79 SEK
291% Upside
Highest
Price Target
14.7 SEK
893% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Oncopeptides AB
does not pay dividends
Shareholder Yield

Current shareholder yield for ONCO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ONCO Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ONCO stock?

The intrinsic value of one ONCO stock under the Base Case scenario is 2.44 SEK.

Is ONCO stock undervalued or overvalued?

Compared to the current market price of 1.48 SEK, Oncopeptides AB is Undervalued by 39%.

Back to Top